Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Phase I study of an oral formulation of ZD9331 administered daily for 28 days.

Sawyer MB, Ratain MJ, Bertucci D, Smith RP, Schilsky RL, Vogelzang NJ, Shulman K, Douglass EC, Fleming GF. Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol. 2003 May 01; 21(9):1859-65.

View in: PubMed